Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 420-380-5 | CAS number: 136465-81-1
A 28-day repeated oral administration study of subacute toxicity in the rat was conducted with PTH-decahydroamide. The main study dose levels were set using data from 5-day preliminary toxicity investigation. Range-finding results indicated suitable dose levels were 0, 30, 150 and 600 mg/kg bw/day. The study design was based on the test guidelines set out in EEC Directive 92/69/EEC, B.7 subacute toxicity - oral, 1992 and OECD Test Method No. 407, Repeated Dose Oral Toxicity - Rodent, 1981.
PTH-Decaydroamide was administered daily by oral gavge to groups of five male and five female Wistar rats. The test guideline parameters - clinical signs, bodyweights, food consumption, ophthalmoscopy, clinical pathology, haematology, organ weights, terminal necropsy and subsequent histopathology were completed in accordance with the test methods.
Formulations of PTH-decahydroamide were confirmed by analysis to be accurate, stable and homogeneous.
There were no teatment-related findings of any toxicological significance in the animals dosed at 30 or 150 mg/kg bw/day.
In the 600 mg/kg bw/day group, five of the rats died (on treatment days 6, 7 or 14) and the remaining five were humanely terminated on welfare grounds on Day 18. The marked signs of toxicity, observed ante-mortem, included clinical signs of convulsive movements, abnormal posture, abnormal gait, recumbency and laboured respiration. Decreased red blood cell counts and reduced haemoglobin content were recorded in the males and females; decreased mean corpuscular haemoglobin concentration and an increased mean corpuscular volume were noted among the males only. Total protein and albumin levels were reduced for males and females and the inorganic phosphate levels were increased in both sexes. Increased liver enzyme activities were recorded for one male rat. Necropsy of the high dose rats revealed vacuolation or centrilobular necrosis in the liver of four males and one female.
Based on the results of the repeated administration of PTH-decahydroamide at 30, 150 or 600 mg/kg bw/day, the no observed effect level (NOEL) was 150 mg/kg bw/day and the LOAEL was 600 mg/kg bw/day.
The marked effects observed at 600 mg/kg bw/day including mortality, functional disturbances and toxicologically significant effects (e.g. convulsions) indicate consideration of the risk phrase R48 "Danger of serious damage to health by prolonged exposure". However, this is only appropriate where effects are observed in rats following oral administration at 50 mg/kg bw/day in a repeated administration study or at levels circa three-fold higher in a subacute study. Since the effects were not apparent at 150 mg/kg bw/day and only observed at the next higher dose level, classification as R48 or STOT-RE Cat 1 or 2 is not considered appropriate for PTH-decahydroamide.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again